|
Last month, 12 medical groups and health systems participating in the Cardiovascular Disease (CVD) Cohort of the Innovator Track met in St. Louis, MO, to mark the end of their yearlong effort to learn how providers can better identify and manage CVD risk among their patients with Type 2 diabetes.
In addition to reporting T2G Core Track measures, the participants in this cohort committed to reporting quarterly on several CVD-related measures:
- Non-tobacco users
- Daily aspirin or anti-platelet agent use
- Lipid management for secondary prevention
To improve their results on these measures, participants employed a variety of interventions such as patient and provider education, electronic health record (EHR) improvement, care redesign, and enhanced documentation.
We are excited to preview results from the Innovator Track CVD Cohort during our next monthly campaign webinar, taking place July 18. Participants are currently working on formal case studies detailing their work in the cohort and their lessons learned. We look forward to sharing the case studies with you in the fall!
Questions? Email us at together2goal@amga.org
|
